What is actually in short supply

This is not a blanket estradiol shortage. Supply is uneven by manufacturer and by dosing schedule, which is why one pharmacy tells you the patch is unavailable and another two miles away fills it without comment.

The pressure has fallen hardest on twice-weekly generic estradiol transdermal systems, particularly those made by Amneal, Noven and Zydus. Once-weekly patches — Climara and the generics from Viatris and Sandoz — have generally remained available. The American Society of Health-System Pharmacists tracks the situation product by product on its drug shortage page, and that listing changes week to week.

One point that confuses people: the FDA has not declared a formal national shortage of estradiol patches. A product can be difficult to obtain at the pharmacy counter without meeting the regulatory definition of a shortage, and that gap is exactly where most women are currently stuck.

Why it happened

Demand rose faster than manufacturing could follow. Prescriptions for estrogen patches climbed roughly 162% over two years, and that curve steepened after the FDA moved in November 2025 to strip the boxed warning from menopausal hormone therapy labels. Women who had been refused hormone therapy for years, or who had refused it themselves after reading the old warning, began asking for it.

Transdermal patches are also genuinely hard to make. The drug has to stay stable in an adhesive matrix and release at a predictable rate for three or seven days on skin that sweats, stretches and gets wet. Adding a production line is not a matter of running the existing one longer.

What to do this week

  1. Call before you drive. Ask the pharmacy to check the specific manufacturer and strength, not just "the estradiol patch." Inventory varies by wholesaler, chain and region.
  2. Ask about the once-weekly version. If you are on a twice-weekly patch, the once-weekly products have been less affected. This is a prescription change, so your prescriber has to make it.
  3. Ask your prescriber about a different route. Gel, spray and vaginal rings deliver estradiol through the skin or mucosa and skip the same first-pass liver metabolism that the patch does. See our guide to equivalent doses across forms before that appointment so you can ask a specific question.
  4. Do not ration or cut patches on your own. Cutting a matrix patch is sometimes done under supervision, but reservoir-type systems can dump their contents if cut. Stretching a three-day patch to five days produces a trough in blood levels and usually a return of symptoms.
  5. Ask for a 90-day supply when stock allows. If your insurance permits it, this removes you from the month-to-month scramble.

What not to do

Compounded estradiol is widely marketed as a workaround. Compounded hormone preparations are not FDA-approved, batch potency is not verified the way it is for approved products, and the professional societies have consistently advised against them when an approved product exists. A supply problem is a poor reason to move to an unverified product.

Ordering patches from overseas pharmacies carries the same problem in a different wrapper: you cannot confirm what you are getting.

How long this lasts

Industry analysts expect the acute phase to run through late 2026, with intermittent gaps possibly continuing into 2027 and 2028 as manufacturers add capacity. Plan on the assumption that this is a year-long inconvenience rather than a two-week one, which is another argument for settling on an alternative form with your prescriber rather than waiting it out refill by refill.

When to call your prescriber rather than wait

  • You have run out entirely and symptoms have returned.
  • You had a surgical menopause or premature ovarian insufficiency — stopping estrogen in these situations is not a minor interruption, because the therapy is replacing what your body would otherwise still be making.
  • You are switching form or dose and are unsure how to overlap the change.

Once-weekly versus twice-weekly: what the difference means for you

Twice-weekly patches are changed every three to four days; once-weekly patches stay on for seven. The blood level profile differs slightly — twice-weekly systems tend to hold a flatter curve, once-weekly ones drift down more toward the end of the wear period, and some women notice symptoms creeping back on day six or seven.

That is worth knowing before a forced switch, because if symptoms return late in the week after moving to a once-weekly patch, the answer is usually a dose adjustment rather than a conclusion that the patch is not working.

If you are on a combination patch

Some patches deliver estradiol together with a progestogen — estradiol with levonorgestrel or with norethindrone acetate. If yours is one of these and it becomes unavailable, the substitution is not a like-for-like swap of an estrogen product. Both hormones have to be replaced, either with another combination patch or with a separate estrogen plus a separate progestogen. This is the situation where a pharmacy substitution without a prescriber conversation goes wrong most often.

Signs the switch has not landed right

Give any change several weeks before judging it, but these are the signals to report rather than tolerate:

  • Hot flashes and night sweats returning after they had settled
  • Sleep breaking up again in the second half of the night
  • Return of vaginal dryness or urinary symptoms
  • New irregular bleeding — this always warrants a call rather than a wait
  • Skin reaction at the site: redness that does not settle, or the patch failing to stick

Practical steps that reduce the scramble

  • Ask for a 90-day supply when stock allows and your plan permits it.
  • Ask the pharmacy to order rather than cancel. Many will source a specific manufacturer if asked; the default is often to report it unavailable.
  • Ask whether the prescription can be written to allow manufacturer substitution so the pharmacy can dispense whichever equivalent generic is in stock.
  • Keep one spare box once supply steadies, so a delay never becomes a gap.

The wider context

This shortage is a side effect of something largely positive: after the FDA moved to remove the boxed warning from menopausal hormone therapy in November 2025, women who had been discouraged from treatment for two decades began asking for it. Demand of that shape arriving at a manufacturing base built for the old demand produces exactly this. It is worth holding both facts at once — the access problem is real, and the reason behind it is that the treatment is finally being offered to the women who need it.